Can pinaverium bromide tablets be taken long-term?

Pivmecillinam is not indicated for long-term use. It is a narrow-spectrum penicillin antibiotic specifically approved for the treatment of acute bacterial cystitis in women and, in some jurisdictions, for certain susceptible Gram-negative urinary tract infections. Its mechanism of action involves inhibition of bacterial cell wall synthesis via binding to penicillin-binding protein 2 (PBP2), leading to bactericidal activity against target organisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

Extended or prophylactic use of pivmecillinam is not supported by clinical evidence and carries significant risks—including the development of antimicrobial resistance, disruption of normal microbiota, and potential for Clostridioides difficile infection. Moreover, prolonged exposure increases the likelihood of selecting for resistant strains, particularly those expressing extended-spectrum beta-lactamases (ESBLs) or other resistance determinants.

In clinical practice, pivmecillinam is prescribed for short courses—typically 3 to 7 days—based on infection severity, local resistance patterns, and patient-specific factors (e.g., renal function, allergy history). Routine long-term administration is contraindicated. If recurrent urinary tract infections are suspected, further diagnostic evaluation—including urine culture with susceptibility testing, imaging, and assessment for anatomical or functional abnormalities—is essential before considering alternative management strategies, such as targeted prophylaxis with non-antibiotic agents or carefully selected, intermittent antibiotic regimens under specialist supervision.